Erythropoietin and Engineered Innate Repair Activators
Erythropoietin (EPO) is a pleiotropic type I cytokine that has been identified as a major endogenous tissue protective molecule. In response to injury, EPO and a distinct receptor are expressed with a characteristic temporal and spatial expression pattern. Together, these serve to limit injury and to initiate repair. Administration of EPO in the setting of injury has been shown to be beneficial in a multitude of preclinical models. However, translation into the clinic has been hampered by EPO’s adverse effects, including promotion of thrombosis. Recently, engineered molecules based on EPO’s structure–activity relationships have been developed that are devoid of hematopoietic effects. These compounds are promising candidates for treatment of a wide variety of acute and chronic diseases.
Key wordsInnate immune response Inflammation Tissue damage Tissue protection Healing Drug design Type 1 cytokine
Disclosure of Interest
The authors are officers of Araim Pharmaceuticals and currently hold stocks/shares in the company.
- 8.Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1–14Google Scholar